# US 2019/0314504 A1 · Pharmaceutical compositions comprising meloxicam

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314504 A1
- Document ID: US20190314504A1
- Status: Published application
- Kind: A1
- Application number: 16/454,319
- Filed: 2019-06-27
- Published: 2019-10-17
- Earliest claimed: 2017-06-29
- Assignees: Axsome Therapeutics, Inc.
- Applicants: Axsome Therapeutics, Inc.
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20190314504A1

## CPC

- A61K 47/02: Inorganic compounds
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- C08B 37/0012: {Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof}
- C08B 37/0015: {Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

## Claims

### Claim 1

A method of treating migraine comprising: orally administering a solid dosage form once daily to a human being suffering from a migraine, wherein the solid dosage form comprises: 1) a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and 2) a bicarbonate, wherein orally administering the solid dosage form to the human being results in a Tmax of meloxicam that is shorter than a Tmax of a reference solid dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate, wherein the solid dosage form has been shown to have a median Tmax of meloxicam that is less than 2 hours in human subjects, wherein the human being is selected for having a history of inadequate response to prior migraine treatments, and wherein the human being is free of migraine pain two hours after the dosage form is orally administered to the human being.

### Claim 2 (depends on 1)

The method of claim 1, wherein the solid dosage form contains about 10 mg to about 20 mg of meloxicam.

### Claim 3 (depends on 1)

The method of claim 1, wherein the solid dosage form contains about 15 mg of meloxicam.

### Claim 4 (depends on 1)

The method of claim 1, wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the solid dosage form contains about 50 mg to about 200 mg of the SBEβCD.

### Claim 6 (depends on 1)

The method of claim 1, wherein the solid dosage form contains about 100 mg of the SBEβCD.

### Claim 7 (depends on 1)

The method of claim 1, wherein the bicarbonate is sodium bicarbonate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the solid dosage form contains about 400 mg to about 600 mg of the bicarbonate.

### Claim 9 (depends on 7)

The method of claim 7, wherein the solid dosage form contains about 500 mg of sodium bicarbonate.

### Claim 10 (depends on 1)

The method of claim 1, wherein the solid dosage form further comprises an acid inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the acid inhibitor is a proton pump inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the proton pump inhibitor is esomeprazole, and about 30 mg to about 50 mg of esomeprazole is present in the solid dosage form.

### Claim 13 (depends on 1)

The method of claim 1, wherein the solid dosage form further comprises rizatriptan.

### Claim 14 (depends on 1)

The method of claim 1, wherein the solid dosage form is administered once daily under fasting condition for about 1 to about 15 days.

### Claim 15 (depends on 1)

The method of claim 1, wherein the human being is being treated with another pain medication before the solid dosage form comprising meloxicam is orally administered, and wherein the use of another pain medication may be reduced by at least about 10% after administration of the solid dosage form.

### Claim 16

A method of treating migraine comprising: orally administering a solid dosage form once daily to a human being suffering from a migraine, wherein the solid dosage form comprises: 1) a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and 2) a bicarbonate, wherein orally administering the solid dosage form to the human being results in a Cmax of meloxicam that is at least about 30% higher than a Cmax of a reference solid dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate, wherein the human being is selected for having a history of inadequate response to prior migraine treatments, and wherein the human being is free of migraine pain two hours after the dosage form is orally administered to the human being.

### Claim 17 (depends on 16)

The method of claim 16, wherein the solid dosage form contains about 10 mg to about 20 mg of meloxicam.

### Claim 18 (depends on 16)

The method of claim 16, wherein the solid dosage form contains about 15 mg of meloxicam.

### Claim 19 (depends on 16)

The method of claim 16, wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.

### Claim 20 (depends on 16)

The method of claim 16, wherein the solid dosage form contains about 50 mg to about 200 mg of the SBEβCD.

### Claim 21 (depends on 16)

The method of claim 16, wherein the solid dosage form contains about 100 mg of the SBEβCD.

### Claim 22 (depends on 16)

The method of claim 16, wherein the bicarbonate is sodium bicarbonate.

### Claim 23 (depends on 16)

The method of claim 16, wherein the solid dosage form contains about 400 mg to about 600 mg of the bicarbonate.

### Claim 24 (depends on 22)

The method of claim 22, wherein the solid dosage form contains about 500 mg of sodium bicarbonate.

### Claim 25 (depends on 16)

The method of claim 16, wherein the solid dosage form further comprises an acid inhibitor.

### Claim 26 (depends on 25)

The method of claim 25, wherein the acid inhibitor is a proton pump inhibitor, and the proton pump inhibitor is esomeprazole.

### Claim 27 (depends on 16)

The method of claim 16, wherein the human being is being treated with another pain medication before the solid dosage form comprising meloxicam is orally administered, and wherein the use of another pain medication may be reduced by at least about 10% after administration of the solid dosage form.

### Claim 28 (depends on 26)

The method of claim 26, wherein about 30 mg to about 50 mg of esomeprazole is present in the solid dosage form.

### Claim 29 (depends on 16)

The method of claim 16, wherein the solid dosage form is administered once daily under fasting condition for about 1 to about 15 days.

### Claim 30 (depends on 16)

The method of claim 16, wherein the solid dosage form further comprises rizatriptan.
